ClinicalTrials.gg
CompletedNCT00829244Updated Feb 13, 2014Results posted

CONSORT Randomized Controlled Trial in Assisted Reproductive Technology

A Phase 4 interventional study of GONAL f® prefilled pen and GONAL f® prefilled pen in Infertility, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Switzerland. Open to female participants aged 18 Years to 34 Years. Per ClinicalTrials.gov, last updated 2014-02-13.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 34 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.

Enrollment
12th of 30
200 · median 159
Started
2008
the only one that year
Phase 4
13 of 30
1 open now
Registered
6th of 30
by date
Lead sponsor
8 of 30
Merck KGaA, Darmstadt, Germany

Among the 30 studies testing follitropin alfa in Infertility, this one is the 12th largest by enrollment, is the only one that started in 2008, is one of 13 in phase 4, and was the 6th registered.

Infertility

2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About follitropin alfa

follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 34 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing follitropin alfa in Infertility, or all of them as a file.
02

Study summary

The overall objective of this trial is to compare the ovarian response in assisted reproductive technology (ART) subjects administered GONAL f® according to the 'Consistency in recombinant follicle stimulating hormone [r-FSH] starting doses for individualized treatment' (CONSORT) calculator versus given a standard GONAL f® dose of 150 International Unit (IU) per day.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Infertility
  • Assisted reproductive technology
04

Who can participate

Ages eligible
18 Years to 34 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female subjects justifying an in-vitro fertilization (IVF)/embryo transfer (ET) treatment
  2. Have a male partner with semen analysis within the past 6 months prior to randomization considered adequate to proceed with regular insemination or intracytoplasmic sperm injection (ICSI) according to the center's standard practice. If these criteria are not met, the subject can only be entered if donor sperm will be used
  3. Between her 18th and 35th birthday (35 not included) at the time of the randomization visit
  4. (BMI) lower than 30 kilogram per square meter (kg/m\^2) where the BMI is calculated according to the formula
  5. Have a regular spontaneous ovulatory menstrual cycle between 21 and 35 days in length
  6. Have an early follicular phase (Day 2-4) serum level of basal FSH lower than or equal to 12 International Unit per Liter (IU/L) measured in the center's local laboratory during the screening period (i.e. within 2 months prior to down-regulation start)
  7. Presence of both ovaries
  8. Normal uterine cavity, which in the investigator's opinion is compatible with pregnancy
  9. Have a negative cervical papanicolaou (PAP) test within the last 6 months prior to randomization
  10. Have at least 1 wash-out cycle (defined as greater than or equal to 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotropin releasing hormone (GnRH) agonist therapy
  11. Willing and able to comply with the protocol for the duration of the trial
  12. Have given written , prior to any trial-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care

Exclusion criteria

Exclusion Criteria:

  1. Have greater than or equal to 2 previous ART cycles with a poor response to gonadotrophin stimulation (defined as lower than or equal to 5 mature follicles and/or lower than or equal to 3 oocytes collected) or have greater than or equal to 2 previous ART cycles with a hyper response (defined as greater than or equal to 25 oocytes retrieved)
  2. Any medical condition, which in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug. In case of doubt, the subject in question should be discussed with Merck Serono's Medical responsible
  3. Have previous severe ovarian hyperstimulation syndrome (OHSS)
  4. Polycystic ovary syndrome (PCOS; Rotterdam criteria) to reduce the risk of the occurrence of OHSS
  5. Presence of endometriosis requiring treatment
  6. Uterine myoma requiring treatment
  7. Any to being pregnant and/or carrying a pregnancy to term
  8. Extra-uterine pregnancy within the last 3 months prior to screening
  9. History of 3 or more miscarriages (early or late miscarriages) due to any cause
  10. Tumors of the hypothalamus and pituitary gland
  11. Ovarian enlargement or cyst of unknown etiology
  12. Ovarian, uterine or mammary cancer
  13. A systemic disease
  14. Known infection with (HIV), or C virus in the trial subject or her male partner,
  15. Abnormal gynecological bleeding of undetermined origin
  16. Known allergy or to human gonadotrophin preparations,
  17. Any active substance abuse or history of drug medication or alcohol abuse in the past 5 years prior to the screening visit
  18. Entered previously into this trial or simultaneous participation in another clinical trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    CONSORT Dosing

    GONAL-f® dose based on subject baseline characteristics determined according to the CONSORT calculator

    Drug: GONAL f® prefilled pen

  • Active comparator
    Standard Dosing

    GONAL-f® at a standard dose of 150 IU per day

    Drug: GONAL f® prefilled pen

Interventions

  • GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only

    Also known as: Follitropin alfa, Recombinant human follicle stimulating hormone (r-hFSH), GONAL-f® Prefilled Pen

  • GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.

    Also known as: Follitropin alfa, r-hFSH, GONAL-f® Prefilled Pen

06

What researchers measure

Primary outcomes

  1. Number of Oocytes Retrieved Per Participant

    Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

    Time frame: 34-38 hours post-recombinant human choriogonadotropin (hCG) (OPU)

Secondary outcomes

  1. Total GONAL-f® Dose

    Time frame: Start of treatment until end of stimulation cycle (approximately 28 days)

  2. Mean GONAL-f® Daily Dose

    Time frame: Start of treatment until end of stimulation cycle (approximately 28 days)

  3. Total Number of GONAL-f® Stimulation Treatment Days

    Time frame: Start of treatment until end of stimulation cycle (approximately 28 days)

  4. Number of Participants With Cancelled Cycles Due to Excessive or Inadequate Response to Treatment

    Number of participants with cancelled cycles due to excessive or inadequate response was evaluated. An excessive response: greater than or equal to 25 oocytes which could put the participant at risk of OHSS; An inadequate response: defined as 3 or less follicles of greater than or equal to 12 millimeter (mm) developing following at least 7 days of GONAL-f® treatment.

    Time frame: Start of treatment until Day 15-20 post-hCG

  5. Percentage of Participants With Biochemical Pregnancies

    Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum and that does not develop into a clinical pregnancy.

    Time frame: Start of treatment until Day 15-20 Post-hCG

  6. Number of Participants With Fetal Sacs and Fetal Hearts

    Number of participants with fetal sacs and fetal hearts (with activity) as seen on an ultrasound scan to confirm clinical pregnancy.

    Time frame: Day 35-42 Post-hCG

  7. Implantation Rate

    Implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100.

    Time frame: Day 35-42 Post-hCG

  8. Number of Participants With Multiple Pregnancies

    Multiple pregnancy was defined as 2 or more fetal hearts with activity.

    Time frame: Day 35-42 Post-hCG

  9. Serum Progesterone (P4) Levels

    Time frame: End of stimulation cycle (approximately 28 days)

  10. Percentage of Participants With Clinical Pregnancy

    Clinical pregnancy is defined by the number of sacs and hearts with activity per ultrasound scan performed on Day 35-42 post-hCG.

    Time frame: Day 35-42 Post-hCG

  11. Number of Participants With OHSS

    OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

    Time frame: Start of treatment until Day 15-20 Post-hCG

  12. Pregnancy Outcome - Number of Participants With Pregnancy and Their Outcome

    Pregnancy outcomes are live outcome (live infant) and non-live outcome (non-live infant) or unknown outcome (subject lost to follow-up).

    Time frame: up to 9 month (following the end of treatment)

07

Results

Posted Sep 7, 2012

Participant flow

Participants were enrolled at 22 clinical trial centers in 9 European countries and 1 center in Chile. Recruitment period: 29 August 2008 to 21 January 2010.

Participant flow — Overall Study
MilestoneGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Started96104
Completed8283
Not completed1421
Withdrew: Adverse event13
Withdrew: Protocol violation10
Withdrew: Lack of ovarian response to stimulation95
Withdrew: Ovarian hyperstimulation syndrome (ohss)16
Withdrew: No fertilization22
Withdrew: All embryos discarded03
Withdrew: No embryo cleavage02

Outcome measures

PrimaryNumber of Oocytes Retrieved Per Participant

Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

Time frame:
34-38 hours post-recombinant human choriogonadotropin (hCG) (OPU)
Reported as:
Mean · oocytes
Number of Oocytes Retrieved Per Participant
oocytesGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Number of Oocytes Retrieved Per Participant10.0 ± 5.611.8 ± 5.3
Statistical analysis
  • GONAL-f ® CONSORT Calculator vs GONAL-f ® Standard Treatment · ANOVA · p = 0.037 · Mean difference (final values): -1.7 · 95% CI -3.3 to -0.1
SecondaryTotal GONAL-f® Dose
Time frame:
Start of treatment until end of stimulation cycle (approximately 28 days)
Reported as:
Mean · IU
Total GONAL-f® Dose
IUGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Total GONAL-f® Dose1288.54 ± 300.951809.95 ± 546.90
Statistical analysis
  • GONAL-f ® CONSORT Calculator vs GONAL-f ® Standard Treatment · ANOVA · p = <0.001 · Mean difference (final values): -511.37 · 95% CI -638.78 to -383.96
SecondaryMean GONAL-f® Daily Dose
Time frame:
Start of treatment until end of stimulation cycle (approximately 28 days)
Reported as:
Mean · IU
Mean GONAL-f® Daily Dose
IUGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Mean GONAL-f® Daily Dose121.49 ± 22.56167.43 ± 30.79
Statistical analysis
  • GONAL-f ® CONSORT Calculator vs GONAL-f ® Standard Treatment · ANOVA · p = <0.001 · Mean difference (final values): -45.60 · 95% CI -53.75 to -37.46
SecondaryTotal Number of GONAL-f® Stimulation Treatment Days
Time frame:
Start of treatment until end of stimulation cycle (approximately 28 days)
Reported as:
Mean · days
Total Number of GONAL-f® Stimulation Treatment Days
daysGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Total Number of GONAL-f® Stimulation Treatment Days10.6 ± 1.710.7 ± 1.6
Statistical analysis
  • GONAL-f ® CONSORT Calculator vs GONAL-f ® Standard Treatment · ANOVA · p = 0.933 · Mean difference (final values): 0.0 · 95% CI -0.4 to 0.5
SecondaryNumber of Participants With Cancelled Cycles Due to Excessive or Inadequate Response to Treatment

Number of participants with cancelled cycles due to excessive or inadequate response was evaluated. An excessive response: greater than or equal to 25 oocytes which could put the participant at risk of OHSS; An inadequate response: defined as 3 or less follicles of greater than or equal to 12 millimeter (mm) developing following at least 7 days of GONAL-f® treatment.

Time frame:
Start of treatment until Day 15-20 post-hCG
Reported as:
Number · Participants
Number of Participants With Cancelled Cycles Due to Excessive or Inadequate Response to Treatment
ParticipantsGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Inadequate response95
Excessive response (Risk of OHSS)16
SecondaryPercentage of Participants With Biochemical Pregnancies

Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum and that does not develop into a clinical pregnancy.

Time frame:
Start of treatment until Day 15-20 Post-hCG
Reported as:
Number · percentage of participants
Percentage of Participants With Biochemical Pregnancies
percentage of participantsGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Percentage of Participants With Biochemical Pregnancies47.744.1
Statistical analysis
  • GONAL-f ® CONSORT Calculator vs GONAL-f ® Standard Treatment · Percent difference: 3.6 · 95% CI -11.0 to 18.2
SecondaryNumber of Participants With Fetal Sacs and Fetal Hearts

Number of participants with fetal sacs and fetal hearts (with activity) as seen on an ultrasound scan to confirm clinical pregnancy.

Time frame:
Day 35-42 Post-hCG
Reported as:
Number · participants
Number of Participants With Fetal Sacs and Fetal Hearts
participantsGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Missing (fetal sacs and fetal hearts)4757
0 (fetal sacs)61
1 (fetal sacs)2725
2 (fetal sacs)510
3 (fetal sacs)10
0 (fetal hearts)83
1 (fetal hearts)2524
2 (fetal hearts)59
3 (fetal hearts)10
SecondaryImplantation Rate

Implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100.

Time frame:
Day 35-42 Post-hCG
Reported as:
Mean · percent sacs per embryo
Implantation Rate
percent sacs per embryoGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Implantation Rate31.1 ± 41.331.2 ± 40.8
Statistical analysis
  • GONAL-f ® CONSORT Calculator vs GONAL-f ® Standard Treatment · ANOVA · p = 0.926 · Mean difference (final values): 0.6 · 95% CI -12.3 to 13.6
SecondaryNumber of Participants With Multiple Pregnancies

Multiple pregnancy was defined as 2 or more fetal hearts with activity.

Time frame:
Day 35-42 Post-hCG
Reported as:
Number · participants
Number of Participants With Multiple Pregnancies
participantsGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Number of Participants With Multiple Pregnancies69
SecondarySerum Progesterone (P4) Levels
Time frame:
End of stimulation cycle (approximately 28 days)
Reported as:
Mean · nmol/L
Serum Progesterone (P4) Levels
nmol/LGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Serum Progesterone (P4) Levels5.41 ± 7.574.88 ± 2.22
Statistical analysis
  • GONAL-f ® CONSORT Calculator vs GONAL-f ® Standard Treatment · ANOVA · p = 0.235 · Mean difference (final values): 0.93 · 95% CI -0.61 to 2.47
SecondaryPercentage of Participants With Clinical Pregnancy

Clinical pregnancy is defined by the number of sacs and hearts with activity per ultrasound scan performed on Day 35-42 post-hCG.

Time frame:
Day 35-42 Post-hCG
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Pregnancy
percentage of participantsGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Percentage of Participants With Clinical Pregnancy36.035.5
Statistical analysis
  • GONAL-f ® CONSORT Calculator vs GONAL-f ® Standard Treatment · Percent difference: 0.6 · 95% CI -13.5 to 14.6
SecondaryNumber of Participants With OHSS

OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

Time frame:
Start of treatment until Day 15-20 Post-hCG
Reported as:
Number · participants
Number of Participants With OHSS
participantsGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Number of Participants With OHSS613
SecondaryPregnancy Outcome - Number of Participants With Pregnancy and Their Outcome

Pregnancy outcomes are live outcome (live infant) and non-live outcome (non-live infant) or unknown outcome (subject lost to follow-up).

Time frame:
up to 9 month (following the end of treatment)
Reported as:
Number · participants
Pregnancy Outcome - Number of Participants With Pregnancy and Their Outcome
participantsGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Live outcomes2425
Non-live outcomes23
Unknown outcomes55

Adverse events

Collected over Adverse Events (AEs) were collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the final treatment examination, on Day 15-20 of the post-treatment assessment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GONAL-f ® CONSORT Calculator—4/96 (4.2%)40/96 (41.7%)
GONAL-f ® Standard Treatment—3/104 (2.9%)48/104 (46.2%)
Most frequent serious events
Most frequent serious events
EventGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
Ovarian hyperstimulation syndromeReproductive system and breast disorders2/962/104
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/960/104
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/960/104
UrticariaSkin and subcutaneous tissue disorders0/961/104
Most frequent other events
Most frequent other events
EventGONAL-f ® CONSORT CalculatorGONAL-f ® Standard Treatment
HeadacheNervous system disorders18/9625/104
Ovarian hyperstimulation syndromeReproductive system and breast disorders5/9611/104
Adnexa uteri painReproductive system and breast disorders9/968/104
Procedural painInjury, poisoning and procedural complications9/965/104
NauseaGastrointestinal disorders8/969/104
Abdominal distensionGastrointestinal disorders8/963/104

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GONAL-f ® CONSORT CalculatorGONAL-f ® Standard TreatmentTotal
<=18 years000
Between 18 and 65 years96104200
>=65 years000
Age, Continuous
Age, Continuous(years)GONAL-f ® CONSORT CalculatorGONAL-f ® Standard TreatmentTotal
Mean30.0 ± 2.930.6 ± 2.630.3 ± 2.8
Sex: Female, Male
Sex: Female, Male(Participants)GONAL-f ® CONSORT CalculatorGONAL-f ® Standard TreatmentTotal
Female96104200
Male000
Region of Enrollment
Region of Enrollment(participants)GONAL-f ® CONSORT CalculatorGONAL-f ® Standard TreatmentTotal
Chile7815
Denmark262652
France6511
Germany131629
Italy101020
Netherlands5611
Spain4610
Sweden8715
Switzerland111425
United Kingdom6612
Serum Anti-Mullerian Hormone (AMH)
Serum Anti-Mullerian Hormone (AMH)(nanogram/milliliter (ng/mL))GONAL-f ® CONSORT CalculatorGONAL-f ® Standard TreatmentTotal
Mean2.705 ± 1.8702.399 ± 1.4922.551 ± 1.692
Serum Progesterone (P4)
Serum Progesterone (P4)(nanomole/liter (nmol/L))GONAL-f ® CONSORT CalculatorGONAL-f ® Standard TreatmentTotal
Mean2.934 ± 2.3282.803 ± 2.2912.868 ± 2.303
08

Study locations

1 site
  • Research Site
    Geneva, Switzerland
09

References and documents

Publications

  • Olivennes F, Trew G, Borini A, Broekmans F, Arriagada P, Warne DW, Howles CM. Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reprod Biomed Online. 2015 Mar;30(3):248-57. doi: 10.1016/j.rbmo.2014.11.013. Epub 2014 Dec 15. PubMed 25596910 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2009
First posted
Jan 26, 2009
Start
Aug 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Sep 7, 2012
Last update
Feb 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00829244
Responsible party
Sponsor
First posted
Jan 26, 2009
Start date
Aug 2008
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Sep 7, 2012
Last update
Feb 13, 2014

Study contacts

Pablo Arriagada, MD
study director · Merck Serono S.A., Geneva
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion